Fig. 2.

Effect of route of administration of NaCl-rich aCSF and/or anti-ouabain Ab on MAP (A) or HR (B) recorded after the indicated treatments in WT mice. Infusions [icv and/or subcutaneous (sc)] of substances were carried out for a period of 8 days as described in materials and methods, and blood pressures and HRs were measured on the last day of treatment via an indwelling fluid-filled catheter that had been implanted on the previous day; n = 5 to 6 in each group. Values represent means ± SE. *P < 0.05 vs. icv aCSF group. NS-Fab, nonspecific sheep IgG antibody Fab fragments (0.65 nmol/day).